Expert Interview
Exploring the Breakthrough of VK2735 in Metabolic Disorders: Insights from Viking Therapeutics' Phase 1 Study (oral formulation)
Ticker(s): VKTXInstitution: Harvard Medical School
- Medical Director, Obesity Clinic Program and Inpatient Diabetes Program & Associate Professor, Harvard Medical School.
- Manages ~1,000 patients with diabetes.
- Co-Investigator of two landmark studies: the national Diabetes Prevention Program and the Look AHEAD (Action for Health in Diabetes) Study.
- Research interests include diabetes and obesity, metabolic syndrome and obesity and cardiovascular disease with a focus on understanding metabolic and cardiovascular benefits of lifestyle changes and weight loss.
How does VK2735's mechanism as a dual GLP-1/GIP receptor agonist potentially benefit patients with obesity, compared to other existing treatments?
Added By: catalin_adminCan you discuss the significance of the dose-dependent weight reduction observed in the VK2735 study, and how it may influence future dosing strategies?
Added By: catalin_adminGiven the reported tolerability of VK2735, how does its safety profile stand out in comparison to other drugs in its class, especially regarding gastrointestinal side effects?
Added By: catalin_adminBased on the preliminary evaluation suggesting longer treatment durations with VK2735 may yield further weight reductions, what are your expectations for its long-term efficacy and patient adherence?
Added By: catalin_adminHow do the exploratory pharmacodynamic measures from the Phase 1 study, like body weight changes, inform us about VK2735's potential clinical application in obesity management?
Added By: catalin_adminCould you elaborate on the importance of the placebo-adjusted mean weight loss results in VK2735's study, particularly in the context of clinical relevance?
Added By: catalin_adminConsidering the proportion of subjects achieving significant weight loss with VK2735, how might this impact patient outcomes and expectations in a real-world setting?
Added By: catalin_adminWith Phase 2 trials planned, what are the anticipated next steps for VK2735's development, and what should clinicians and patients expect in terms of its advancement and availability in treating obesity?
Added By: catalin_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
